Literature DB >> 31918277

Advances in research into the mechanisms of Chinese Materia Medica against acute lung injury.

Zihe Ding1, Renxing Zhong1, Tianyi Xia1, Yanni Yang1, Na Xing1, Wujing Wang1, Yi Wang2, Bingyou Yang3, Xiaobo Sun4, Zunpeng Shu5.   

Abstract

Acute lung injury (ALI) is a common and serious disease. Numerous treatment options are available but they do not improve quality of life or reduce mortality for ALI patients. Here, we review the treatments for ALI to provide basic data for ALI drug therapy research and development. Chinese Materia Medica (CMM) has long been the traditional clinical approach in China for the treatment of ALI and it has proven efficacy. The continued study of CMM has disclosed new potential therapeutic ingredients for ALI. However, few reviews summarize the currently available CMM-based anti-ALI drugs. Therefore, the systematic analysis of research progress in anti-ALI CMM is of great academic and clinical value. The aim of the present review is to describe CMM-based research progress in ALI treatment. Data were compiled by electronic retrieval (CNKI, SciFinder, PubMeds, Google Scholar, Web of Science) and from articles, patents and ethnopharmacological literature in university libraries were systematically studied. This review introduces progress in research on the etiology and mechanisms of ALI, the anti-ALI theory and modes of action in traditional Chinese medicine (TCM), anti-ALI active constituents of CMM, research progress in experimental methods of CMM anti-ALI, the anti-ALI molecular mechanisms of CMM, the anti-ALI efficacy of CMM formulae, and the potential toxicity of CMM and the antidotes for it. Scholars have investigated the anti-ALI molecular mechanism of CMM from various direction and have made substantial progress. This research explored the above aspects, enriched the anti-ALI theory of CMM and established the clinical significance and developmental prospects of ALI treatment by CMM. Because of the high frequency of drugs such as glucocorticoids or antibiotics, Western medicine lacks the advantages of CMM in terms of overall anti-ALI efficacy. In the future, the development of CMM-based anti-ALI therapies will become a major trend in the field of ALI drug development. Successful clinical safety and efficacy validations will promote and encourage the use of CMM. It provides fundamental theoretical support for the discovery and use of CMM resources through the comprehensive analysis of various anti-ALI CMM report databases.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Acute lung injury; Anti-ALI disease ingredient; Anti-ALI effect; Chinese Materia Medica; Review

Year:  2019        PMID: 31918277     DOI: 10.1016/j.biopha.2019.109706

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  9 in total

1.  Integrated Pharmacology Reveals the Molecular Mechanism of Gegen Qinlian Decoction Against Lipopolysaccharide-induced Acute Lung Injury.

Authors:  Wei Li; Zihe Ding; Ying Chen; Yi Wang; Mingming Peng; Chuanqiu Li; Han Zhang; Renxing Zhong; Tianyi Xia; Luyang Zhong; Mantong Zhao; Mengru Yang; Yimin Yue; Lanyuan Liang; Xia Cao; Zunpeng Shu
Journal:  Front Pharmacol       Date:  2022-05-13       Impact factor: 5.988

2.  Discovery of a Novel MyD88 Inhibitor M20 and Its Protection Against Sepsis-Mediated Acute Lung Injury.

Authors:  Jiali Song; Daoxing Chen; Yingqiao Pan; Xueqin Shi; Qian Liu; Xiaoyao Lu; Ximing Xu; Gaozhi Chen; Yuepiao Cai
Journal:  Front Pharmacol       Date:  2021-11-29       Impact factor: 5.810

3.  Gu-Ben-Zhi-Ke-Zhong-Yao Alleviated PM2.5-Induced Lung Injury via HMGB1/NF-κB Axis.

Authors:  Wenxiao Hou; Hongchun Zhang; Meng Jiang; Yina Wu; Tao Li; Luhong Cong; Jun Duan
Journal:  J Healthc Eng       Date:  2022-03-30       Impact factor: 2.682

4.  Puerarin ameliorates acute lung injury by modulating NLRP3 inflammasome-induced pyroptosis.

Authors:  Dasheng Cai; Yue Zhao; Fang Yu
Journal:  Cell Death Discov       Date:  2022-08-18

5.  A sesquiterpene isolated from the stems and leaves of Dioscorea opposita thunb. Transforms the composition of immune cells through ERβ in a mouse model of LPS-induced lung injury.

Authors:  Mengnan Zeng; Beibei Zhang; Yingjie Ren; Shengchao Wang; Pengli Guo; Meng Liu; Qinqin Zhang; Jufang Jia; Jinyue Li; Xiaoke Zheng; Weisheng Feng
Journal:  Heliyon       Date:  2022-09-02

6.  XueFu ZhuYu Decoction Alleviates Cardiopulmonary Bypass-Induced NLRP3 Inflammasome-Dependent Pyroptosis by Inhibiting IkB-α/NF-κB Pathway in Acute Lung Injury Rats.

Authors:  Hui Li; Wenlei Zhang; Qiaoqin Lou; Yuejin Chang; Zhenhao Lin; Lingli Lou
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-10       Impact factor: 2.650

7.  Pinelliae rhizoma alleviated acute lung injury induced by lipopolysaccharide via suppressing endoplasmic reticulum stress-mediated NLRP3 inflammasome.

Authors:  Ning-Ning Wang; Xian-Xie Zhang; Pan Shen; Cong-Shu Huang; Hui-Fang Deng; Lei Zhou; Lan-Xin Yue; Bao-Ying Shen; Wei Zhou; Yue Gao
Journal:  Front Pharmacol       Date:  2022-08-15       Impact factor: 5.988

Review 8.  Role of gut microbiota in identification of novel TCM-derived active metabolites.

Authors:  Tzu-Lung Lin; Chia-Chen Lu; Wei-Fan Lai; Ting-Shu Wu; Jang-Jih Lu; Young-Mao Chen; Chi-Meng Tzeng; Hong-Tao Liu; Hong Wei; Hsin-Chih Lai
Journal:  Protein Cell       Date:  2020-09-15       Impact factor: 14.870

9.  Systems pharmacology reveals the mechanism of activity of Physalis alkekengi L. var. franchetii against lipopolysaccharide-induced acute lung injury.

Authors:  Yanni Yang; Zihe Ding; Yi Wang; Renxing Zhong; Yanlin Feng; Tianyi Xia; Yuanyuan Xie; Bingyou Yang; Xiaobo Sun; Zunpeng Shu
Journal:  J Cell Mol Med       Date:  2020-03-27       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.